<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7545798\results\search\disease\results.xml">
  <result pre="courier ; font-style : italic;} BMC Infect DisBMC Infect DisBMC" exact="Infectious" post="Diseases1471-2334BioMed CentralLondon pmcid: 75457985450 doi: 10.1186/s12879-020-05450-4 : Research Article"/>
  <result pre="0001 2113 4110Departments of Public Health, School of Health Sciences," exact="Central" post="Michigan University, [8], grid.11951.3d0000 0004 1937 1135Division of Epidemiology,"/>
  <result pre="to the data. Abstract Background The triple burden of COVID-19," exact="tuberculosis" post="and human immunodeficiency virus is one of the major"/>
  <result pre="Abstract Background The triple burden of COVID-19, tuberculosis and human" exact="immunodeficiency" post="virus is one of the major global health challenges"/>
  <result pre="SARS-CoV-2 HIV TB Co-infection Background The triple burden of COVID-19," exact="tuberculosis" post="(TB) and human immunodeficiency virus (HIV) is one of"/>
  <result pre="Background The triple burden of COVID-19, tuberculosis (TB) and human" exact="immunodeficiency" post="virus (HIV) is one of the major and persistent"/>
  <result pre="reported worldwide. Those epidemics are caused by different agents: severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002, Middle East respiratory"/>
  <result pre="worldwide. Those epidemics are caused by different agents: severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002, Middle East respiratory syndrome"/>
  <result pre="Those epidemics are caused by different agents: severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002, Middle East respiratory syndrome coronavirus"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012 and the current of"/>
  <result pre="acute respiratory syndrome coronavirus (SARS-CoV) in 2002, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012 and the current of SARS-CoV-2"/>
  <result pre="of 3.81% % worldwide [7]. HIV, TB and newly Emerging" exact="Infectious" post="Diseases such as Coronavirus epidemics are expected to overlap"/>
  <result pre="3.81% % worldwide [7]. HIV, TB and newly Emerging Infectious" exact="Diseases" post="such as Coronavirus epidemics are expected to overlap in"/>
  <result pre="in countries with a high burden of HIV and TB" exact="infections" post="pose several public health challenges. In fact, TB is"/>
  <result pre="public health challenges. In fact, TB is the leading immune-suppressing" exact="infection" post="and the most common cause of death among HIV-infected"/>
  <result pre="and causing a high mortality rate among people living with" exact="HIV/AIDS" post="over the last ten years [12]. In the post-mortem,"/>
  <result pre="WHO/UNAIDS estimate that overall TB accounts for approximately 25% of" exact="HIV/AIDS" post="related deaths worldwide [13]. How COVID-19 will manifest itself"/>
  <result pre="[14]. Populations infected with HIV and TB, those with undiagnosed" exact="pulmonary" post="TB (PTB), drug-resistant tuberculosis or complex presentations such as"/>
  <result pre="HIV and TB, those with undiagnosed pulmonary TB (PTB), drug-resistant" exact="tuberculosis" post="or complex presentations such as disseminated types and those"/>
  <result pre="spread across the world, many areas face the risk of" exact="infection" post="with SARS-CoV-2 and the obstacles and challenges to sustaining"/>
  <result pre="months. The intersecting coronavirus, TB and HIV epidemics in sub-Saharan" exact="African" post="countries where HIV and TB have the highest prevalence"/>
  <result pre="clinical management and post COVID-19 epidemic TB incidence as COVID-19" exact="pulmonary" post="fibrosis may rapidly increase TB incidence [15]. In fact,"/>
  <result pre="Recent evidence has indicated a substantial association between coronavirus-related Lower" exact="Respiratory" post="Tract Infections (LRTIs) and increased risk of death in"/>
  <result pre="evidence has indicated a substantial association between coronavirus-related Lower Respiratory" exact="Tract" post="Infections (LRTIs) and increased risk of death in immune-compromised"/>
  <result pre="has indicated a substantial association between coronavirus-related Lower Respiratory Tract" exact="Infections" post="(LRTIs) and increased risk of death in immune-compromised individuals"/>
  <result pre="pathogenesis. Nonetheless, severe SARS-CoV can induce the development of rapid" exact="pulmonary" post="fibrosis compared with mild courses of SARS-CoV disease usually"/>
  <result pre="of rapid pulmonary fibrosis compared with mild courses of SARS-CoV" exact="disease" post="usually advanced to organize phase diffuse alveolar damage (DAD)"/>
  <result pre="mild courses of SARS-CoV disease usually advanced to organize phase" exact="diffuse" post="alveolar damage (DAD) and eventual long-term deposition of fibrous"/>
  <result pre="and TB in the nine high burden countries in Sub-Saharan" exact="African" post="(Fig.Â 1). The aim of this study was to"/>
  <result pre="and TB in the nine high burden countries in Sub-Saharan" exact="African" post="Methods The protocol was accepted by the international prospective"/>
  <result pre="with STATA version 14 to compare SARS, MERS or COVID-19" exact="disease" post="severity compared to TB and/or HIV in descriptive analysis."/>
  <result pre="those reporting other outcomes, letters to the editor, theoretical and" exact="incomplete" post="studies were excluded. The outcomes include TB occurrence (before,"/>
  <result pre="for eligibility. Thirty-seven articles were excluded because there were either" exact="incomplete" post="or irrelevant articles. Twenty-one studies were included for qualitative"/>
  <result pre="21 Karim 2020 USA Included percentage of COVID-19/HIV/TB report No" exact="primary" post="data reported 22 Pang 2020 China Included COVID-19/TB cases"/>
  <result pre="with confirmed SARS-CoV -Case series PTB SARS-CoV N/A intravenous immunoglobulin" exact="short" post="course of high-dose corticosteroids Anti TB drugs PTB developed"/>
  <result pre="Kingdom of Saudi Arabia [32] âˆ’13-year-old girl and A 30-year-old" exact="female" post="with confirmed MERS-CoV -Case series PTB MERS-CoV N/A intensive"/>
  <result pre="before MERS-CoV The 13â€‰years old had severe MERS-CoV. However, the" exact="disease" post="severity was moderate with the 30â€‰years old. Both of"/>
  <result pre="recovered from MERS-CoV N/A Singh 2020 India [33] 76-year- old" exact="female" post="with confirmed COVID-19 Case study PTB COVID-19 N/A hydroxychloroquine"/>
  <result pre="[36] 55-year-old male with a history of myelodysplastic Syndrome, immunocompromised," exact="kidney failure" post="and confirmed with COVID-19 Case study Disseminated TB COVID-19"/>
  <result pre="Syndrome, immunocompromised, kidney failure and confirmed with COVID-19 Case study" exact="Disseminated" post="TB COVID-19 N/A COVID-19 convalescent plasma Favipiravir meropenem Ventilatory"/>
  <result pre="last case had LTBI and the second was a previous" exact="MDR-TB" post="All of them developed severe/critical COVID-19 courses All of"/>
  <result pre="also HIV-infected. The median age was 39â€‰years Case series PTB" exact="Disseminated" post="TB COVID-19 N/A Hydroxychloroquine. Ventilatory support Anti-TB drugs N/A"/>
  <result pre="which 113 had confirmed TB. The mean age of the" exact="total" post="sample was 48.9â€‰years Longitudinal matched cohort analysis Confirmed TB,"/>
  <result pre="TB status Latent TB COVID-19 Case series study of 115" exact="bacterial" post="and 62 other viral pneumonia. Controls selected in the"/>
  <result pre="COVID-19 Case series study of 115 bacterial and 62 other" exact="viral pneumonia." post="Controls selected in the same setting. N/A Previous TB:"/>
  <result pre="initial symptom development. N/A N/A Li 2020 China [2] A" exact="total" post="of 549 patients with COVID-19 were enrolled. The median"/>
  <result pre="China [44] âˆ’140 confirmed COVID-19 cases, 2 of whom had" exact="secondary" post="PTB -Retrospective study PTB COVID-19 Non-severe vs Severe COVID-19"/>
  <result pre="whom had secondary PTB -Retrospective study PTB COVID-19 Non-severe vs" exact="Severe" post="COVID-19 N/A N/A Severity COVID-19/TB Severe: 2/58 Not severe:"/>
  <result pre="Age (44.1â€‰Â±â€‰17.9) years Retrospective cohort study PTB COVID-19 Non-severe vs" exact="Severe" post="COVID-19 N/A N/A Severe: 3/229 Not severe: 2/1121 N/A"/>
  <result pre="on previous exposure to TB, relevant symptoms of typical PTB," exact="chest" post="radiographs suggestive of active disease or IGRA (Interferon Gamma"/>
  <result pre="relevant symptoms of typical PTB, chest radiographs suggestive of active" exact="disease" post="or IGRA (Interferon Gamma Release Assay). SARS-CoV or MERS-CoV"/>
  <result pre="PTB, chest radiographs suggestive of active disease or IGRA (Interferon" exact="Gamma" post="Release Assay). SARS-CoV or MERS-CoV was confirmed based on"/>
  <result pre="to COVID-19/TB co-infected cases. Eight out of fourteen had severe/critical" exact="disease" post="course among which one case of SARS-CoV, one of"/>
  <result pre="and two months after SARS-CoV [30]. At day 80 of" exact="disease" post="on convalescence, one of the cases was positive for"/>
  <result pre="had severe COVID-19 before developing PTB. Intravenous immunoglobulin and a" exact="short" post="course of high-dose corticosteroids were indicated during the SARS"/>
  <result pre="administered during the TB course. The said patients remained clinically" exact="stable" post="at follow-up. Cases were stratified by PTB diagnosis. 41.36%"/>
  <result pre="44, 45, 47â€&quot;49]. Among them, SARS-CoV/HIV/TB co-infected case developed mild" exact="disease" post="course, one COVID-19/HIV/TB developed severe COVID-19 and the last"/>
  <result pre="groups were included in the TB occurrence outcome, with a" exact="total" post="sample of 2015 participants. COVID-19 severity included three cohort"/>
  <result pre="three cohort studies and one case control for which the" exact="total" post="sample size was 2074 participants. A total of 22,838"/>
  <result pre="for which the total sample size was 2074 participants. A" exact="total" post="of 22,838 and 23,017 participants were included in recovery"/>
  <result pre="highly likely that both previous SARS-CoV with newly diagnosed PTB" exact="acquired" post="active PTB after contracting SARS. This is so because"/>
  <result pre="analysis of cases also found that SARS-CoV could induce a" exact="transient" post="suppression of cellular immunity that further predisposed patients to"/>
  <result pre="diagnosis, hospitalization, Intensive Care Unit (ICU) admission, and death among" exact="HIV-positive" post="persons receiving ART were greater in men compared to"/>
  <result pre="varied by the nucleoside transcriptase inhibitor (NRTI) regimen and was" exact="lower" post="in patients receiving TDF/FTC versus those receiving other regimens"/>
  <result pre="outcome in mortality rate among COVID-19/HIV/TB co-infection compared to COVID-19/TB" exact="infection" post="is illustrated in Fig. 6. Both those with COVID-19/HIV/TB"/>
  <result pre="less likely to access and be retained in care, yielding" exact="viral" post="suppression of a mere 37% for those age 25â€&quot;34â€‰years"/>
  <result pre="co-existence of those three pandemics may imply vulnerability to COVID-19" exact="infections" post="and increase TB occurrence. Clear diagnostic algorithms, exploration of"/>
  <result pre="Suspected cases of COVID-19 and TB show similar fever and/or" exact="respiratory" post="symptoms (difficult respiration, coughing, chest pain, etc.). COVID-19 RT-PCR"/>
  <result pre="TB show similar fever and/or respiratory symptoms (difficult respiration, coughing," exact="chest" post="pain, etc.). COVID-19 RT-PCR should be done in real-time"/>
  <result pre="done in real-time for differential diagnosis of cases with unknown" exact="respiratory" post="syndromes such as PTB [53]. Due to poor outcomes"/>
  <result pre="culture and drug susceptibility testing (DST) [54]. Instead of collecting" exact="upper" post="respiratory tract specimens, lower respiratory tract specimens, such as"/>
  <result pre="and drug susceptibility testing (DST) [54]. Instead of collecting upper" exact="respiratory" post="tract specimens, lower respiratory tract specimens, such as sputum,"/>
  <result pre="testing (DST) [54]. Instead of collecting upper respiratory tract specimens," exact="lower" post="respiratory tract specimens, such as sputum, bronchoalveolar lavage, and"/>
  <result pre="(DST) [54]. Instead of collecting upper respiratory tract specimens, lower" exact="respiratory" post="tract specimens, such as sputum, bronchoalveolar lavage, and tracheal"/>
  <result pre="same time, the Xpert MTB / RIF assay detects M." exact="tuberculosis" post="and rifampicin resistance within less than two hours [55]."/>
  <result pre="algorithm includes an interrogatory about cough of any duration, fever," exact="short" post="breathing, sore throat, loss of weight, loss of appetite,"/>
  <result pre="confirmed TB, previous TB contact, TB preventive therapies, unsuppressed HIV" exact="viral" post="load and CD4 count â‰¤350 cells/Î¼L. Xpert MTB/RIF assay"/>
  <result pre="Xpert MTB/RIF assay is negative, the culture associated with the" exact="chest" post="X-ray should be requested. If abnormal chest X-ray suggestive"/>
  <result pre="associated with the chest X-ray should be requested. If abnormal" exact="chest" post="X-ray suggestive of TB, start anti-TB drugs, in the"/>
  <result pre="previous COVID-19, previous contact or active TB, HIV positive, HIV" exact="viral" post="load and CD4 count. All people with cough of"/>
  <result pre="CD4 count. All people with cough of any duration, fever," exact="short" post="breathing, sore throat, weight loss, hemoptysis, night sweat, arthralgia"/>
  <result pre="and clinical considerations In the case of concurrent HIV and" exact="tuberculosis" post="infection plus SARS-CoV-2 infection, the additional drug might cause"/>
  <result pre="clinical considerations In the case of concurrent HIV and tuberculosis" exact="infection" post="plus SARS-CoV-2 infection, the additional drug might cause interaction"/>
  <result pre="whether LPV/r and other ART enhance clinical outcomes in severe" exact="symptomatic" post="disease or prevent infection in patients at high- risk"/>
  <result pre="LPV/r and other ART enhance clinical outcomes in severe symptomatic" exact="disease" post="or prevent infection in patients at high- risk of"/>
  <result pre="ART enhance clinical outcomes in severe symptomatic disease or prevent" exact="infection" post="in patients at high- risk of COVID-19 based on"/>
  <result pre="have demonstrated that co-administration of PIs with rifampicin reduces PIs" exact="systemic" post="concentration to less than 75% (cytochrome P 450 induction)"/>
  <result pre="of CYP450 [70]. Additionally, high-dose chloroquine is more toxic than" exact="lower" post="dose [64]. This is why; studies should clarify chloroquine"/>
  <result pre="adapted TB regimens without rifampicin. In contrast, clofazimine used in" exact="MDR-TB" post="is a strong inhibitor of PIs, known substrates [71]."/>
  <result pre="diagnostic. A study showed an association between corticosteroid use and" exact="lower" post="mortality in COVID-19 patients [68]. Using a glucocorticoid in"/>
  <result pre="with TB. Careful use of corticosteroids with low-to-moderate doses in" exact="short" post="courses is advised [68]. Besides, fibrosis and extensive pulmonary"/>
  <result pre="in short courses is advised [68]. Besides, fibrosis and extensive" exact="pulmonary" post="pathology secondary to TB and COVID-19, as defined in"/>
  <result pre="courses is advised [68]. Besides, fibrosis and extensive pulmonary pathology" exact="secondary" post="to TB and COVID-19, as defined in the introduction,"/>
  <result pre="factor for bad TB outcomes in the event of potential" exact="infection" post="or reactivation of TB [72]. This may also induce"/>
  <result pre="infection or reactivation of TB [72]. This may also induce" exact="MDR-TB" post="or extensively drug-resistant tuberculosis (XDR-TB) or recurrent pneumonia. Then,"/>
  <result pre="TB [72]. This may also induce MDR-TB or extensively drug-resistant" exact="tuberculosis" post="(XDR-TB) or recurrent pneumonia. Then, special considerations should be"/>
  <result pre="may also induce MDR-TB or extensively drug-resistant tuberculosis (XDR-TB) or" exact="recurrent" post="pneumonia. Then, special considerations should be taken into account"/>
  <result pre="be taken into account in the clinical management of COVID-19/TB" exact="lung fibrosis." post="Some RCTs are currently underway evaluating the safety and"/>
  <result pre="evaluating the safety and effectiveness of antifibrotic therapies on COVID-19" exact="lung fibrosis" post="[46]. Besides, liver and kidneys toxicities related to severe"/>
  <result pre="pyrazinamide, tenofovir disoproxil, atazanavir/ritonavir, lopinavir/ritonavir as well as HIV induced" exact="nephropathy" post="and hepatitis associated to HIV. Clinical management approach 1."/>
  <result pre="disoproxil, atazanavir/ritonavir, lopinavir/ritonavir as well as HIV induced nephropathy and" exact="hepatitis" post="associated to HIV. Clinical management approach 1. Mild to"/>
  <result pre="should be reviewed as described above. Initial evaluation includes a" exact="chest" post="x-ray, complete blood count (CBC), liver transaminases, renal function,"/>
  <result pre="reviewed as described above. Initial evaluation includes a chest x-ray," exact="complete" post="blood count (CBC), liver transaminases, renal function, inflammatory markers"/>
  <result pre="not part of standard care, may have prognostic value. 2." exact="Severe" post="COVID-19 associated to HIV/TB co-infection: Hospitalized in COVID-19/TB unit"/>
  <result pre="patients [74]. Ventilator support, oxygen through a face mask and" exact="symptomatic" post="therapy should be indicated. Initial evaluation includes chest x-ray/CT-scan"/>
  <result pre="mask and symptomatic therapy should be indicated. Initial evaluation includes" exact="chest" post="x-ray/CT-scan and CBC should be indicated. Liver transaminases and"/>
  <result pre="co-infection: Hospitalized in COVID-19/TB unit with ICU as high-risk patients." exact="Infection" post="control and testing, ventilator support, hemodynamic, and drug therapy"/>
  <result pre="strong evidence against the use of hydroxyethyl starches for the" exact="acute" post="reanimation of adults with COVID-19 in shock [75]. In"/>
  <result pre="shock [75]. In adults with COVID-19 in shock, if the" exact="peripheral" post="oxygen saturation (SpO2) is 75]. Initial evaluation includes chest"/>
  <result pre="the peripheral oxygen saturation (SpO2) is 75]. Initial evaluation includes" exact="chest" post="x-ray/CT-scan and CBC should be indicated. Liver transaminases and"/>
  <result pre="consideration of COVID-19-HIV and TB drug-drug interactions and clinical considerations." exact="Inflammatory" post="markers, D-dimer, cardiac enzymes and ferritin monitoring should be"/>
  <result pre="Therefore, emphasis should be put on the risk of severe" exact="lung fibrosis" post="that may induce MDR-TB or XDR-TB. Ongoing trials are"/>
  <result pre="on the risk of severe lung fibrosis that may induce" exact="MDR-TB" post="or XDR-TB. Ongoing trials are evaluating the safety and"/>
  <result pre="TB co-infected cases due to their synergic roles in inducing" exact="pulmonary" post="fibrosis. Conclusion This is the first systematic review of"/>
  <result pre="that COVID-19 and TB may induce the development of severe" exact="lung disease" post="leading to pulmonary fibrosis in the future, further studies"/>
  <result pre="COVID-19 and TB may induce the development of severe lung" exact="disease" post="leading to pulmonary fibrosis in the future, further studies"/>
  <result pre="may induce the development of severe lung disease leading to" exact="pulmonary" post="fibrosis in the future, further studies are needed with"/>
  <result pre="individuals. More research is needed to explore the effect of" exact="lung fibrosis" post="related to COVID-19 in high burden HIV/TB countries. This"/>
  <result pre="Table 1. Quality assessment of included studies Abbreviations COVID-19 Coronavirus" exact="Disease" post="19 DAD Diffuse Alveolar Damage ICU Intensive Care Unit"/>
  <result pre="assessment of included studies Abbreviations COVID-19 Coronavirus Disease 19 DAD" exact="Diffuse" post="Alveolar Damage ICU Intensive Care Unit IGRA Interferon Gamma"/>
  <result pre="of included studies Abbreviations COVID-19 Coronavirus Disease 19 DAD Diffuse" exact="Alveolar" post="Damage ICU Intensive Care Unit IGRA Interferon Gamma Release"/>
  <result pre="DAD Diffuse Alveolar Damage ICU Intensive Care Unit IGRA Interferon" exact="Gamma" post="Release Assay HIV Human Immunodeficiency Virus LRTIs Lower Respiratory"/>
  <result pre="Intensive Care Unit IGRA Interferon Gamma Release Assay HIV Human" exact="Immunodeficiency" post="Virus LRTIs Lower Respiratory Tract Infections MERS-CoV Middle East"/>
  <result pre="Interferon Gamma Release Assay HIV Human Immunodeficiency Virus LRTIs Lower" exact="Respiratory" post="Tract Infections MERS-CoV Middle East respiratory syndrome coronavirus MDR-TB"/>
  <result pre="Gamma Release Assay HIV Human Immunodeficiency Virus LRTIs Lower Respiratory" exact="Tract" post="Infections MERS-CoV Middle East respiratory syndrome coronavirus MDR-TB Multidrug-resistant"/>
  <result pre="Release Assay HIV Human Immunodeficiency Virus LRTIs Lower Respiratory Tract" exact="Infections" post="MERS-CoV Middle East respiratory syndrome coronavirus MDR-TB Multidrug-resistant TB"/>
  <result pre="Immunodeficiency Virus LRTIs Lower Respiratory Tract Infections MERS-CoV Middle East" exact="respiratory" post="syndrome coronavirus MDR-TB Multidrug-resistant TB NIH National Institute of"/>
  <result pre="Virus LRTIs Lower Respiratory Tract Infections MERS-CoV Middle East respiratory" exact="syndrome" post="coronavirus MDR-TB Multidrug-resistant TB NIH National Institute of Health"/>
  <result pre="Lower Respiratory Tract Infections MERS-CoV Middle East respiratory syndrome coronavirus" exact="MDR-TB" post="Multidrug-resistant TB NIH National Institute of Health NOS Newcastle-Ottawa-Scale"/>
  <result pre="Systematic Reviews and Meta-Analysis PLWH People Living With HIV PTB" exact="Pulmonary" post="TB RIF Rifampicin RT-PCR Real-time polymerase chain reaction SARS-CoV"/>
  <result pre="Pulmonary TB RIF Rifampicin RT-PCR Real-time polymerase chain reaction SARS-CoV" exact="Severe" post="acute respiratory syndrome coronavirus TB Tuberculosis UNAIDS The joint"/>
  <result pre="TB RIF Rifampicin RT-PCR Real-time polymerase chain reaction SARS-CoV Severe" exact="acute" post="respiratory syndrome coronavirus TB Tuberculosis UNAIDS The joint United"/>
  <result pre="RIF Rifampicin RT-PCR Real-time polymerase chain reaction SARS-CoV Severe acute" exact="respiratory" post="syndrome coronavirus TB Tuberculosis UNAIDS The joint United Nations"/>
  <result pre="Rifampicin RT-PCR Real-time polymerase chain reaction SARS-CoV Severe acute respiratory" exact="syndrome" post="coronavirus TB Tuberculosis UNAIDS The joint United Nations Programme"/>
  <result pre="polymerase chain reaction SARS-CoV Severe acute respiratory syndrome coronavirus TB" exact="Tuberculosis" post="UNAIDS The joint United Nations Programme on HIV/AIDS USAID"/>
  <result pre="coronavirus TB Tuberculosis UNAIDS The joint United Nations Programme on" exact="HIV/AIDS" post="USAID U.S. Agency for International Development WHO World Health"/>
  <result pre="for International Development WHO World Health Organization XDR-TB Extensively drug-resistant" exact="tuberculosis" post="Publisherâ€™s Note Springer Nature remains neutral with regard to"/>
  <result pre="of new coronavirus epidemics on HIV-infected patientsAIDS Rev2020221575810.24875/AIDSRev.M2000003132167508 2.LiGFanYLaiYHanTLiZZhouPet al.Coronavirus" exact="infections" post="and immune responsesJ Med Virol202092442443210.1002/jmv.2568531981224 3.CuiJLiFShiZLOrigin and evolution of"/>
  <result pre="coronavirusesNat Rev Microbiol201917318119210.1038/s41579-018-0118-930531947 4.LipsitchMCohenTCooperBRobinsJMMaSJamesLet al.Transmission dynamics and control of severe" exact="acute" post="respiratory syndromeScience (New York, NY)200330056271966197010.1126/science.1086616 5.WallingaJTeunisPDifferent epidemic curves for"/>
  <result pre="Rev Microbiol201917318119210.1038/s41579-018-0118-930531947 4.LipsitchMCohenTCooperBRobinsJMMaSJamesLet al.Transmission dynamics and control of severe acute" exact="respiratory" post="syndromeScience (New York, NY)200330056271966197010.1126/science.1086616 5.WallingaJTeunisPDifferent epidemic curves for severe"/>
  <result pre="respiratory syndromeScience (New York, NY)200330056271966197010.1126/science.1086616 5.WallingaJTeunisPDifferent epidemic curves for severe" exact="acute" post="respiratory syndrome reveal similar impacts of control measuresAm J"/>
  <result pre="syndromeScience (New York, NY)200330056271966197010.1126/science.1086616 5.WallingaJTeunisPDifferent epidemic curves for severe acute" exact="respiratory" post="syndrome reveal similar impacts of control measuresAm J Epidemiol2004160650951610.1093/aje/kwh25515353409"/>
  <result pre="(New York, NY)200330056271966197010.1126/science.1086616 5.WallingaJTeunisPDifferent epidemic curves for severe acute respiratory" exact="syndrome" post="reveal similar impacts of control measuresAm J Epidemiol2004160650951610.1093/aje/kwh25515353409 6.LinQChiuAPZhaoSHeDModeling"/>
  <result pre="control measuresAm J Epidemiol2004160650951610.1093/aje/kwh25515353409 6.LinQChiuAPZhaoSHeDModeling the spread of Middle East" exact="respiratory" post="syndrome coronavirus in Saudi ArabiaStat Methods Med Res20182771968197810.1177/096228021774644229846148 7.collab:"/>
  <result pre="measuresAm J Epidemiol2004160650951610.1093/aje/kwh25515353409 6.LinQChiuAPZhaoSHeDModeling the spread of Middle East respiratory" exact="syndrome" post="coronavirus in Saudi ArabiaStat Methods Med Res20182771968197810.1177/096228021774644229846148 7.collab: World"/>
  <result pre="in Saudi ArabiaStat Methods Med Res20182771968197810.1177/096228021774644229846148 7.collab: World Health OrganizationCoronavirus" exact="disease" post="2019 (COVID-19) Situation Report â€&quot; 1972020 8.SwaminathanSNagendranGHIV and tuberculosis"/>
  <result pre="OrganizationCoronavirus disease 2019 (COVID-19) Situation Report â€&quot; 1972020 8.SwaminathanSNagendranGHIV and" exact="tuberculosis" post="in IndiaJ Biosci200833452753710.1007/s12038-008-0071-219208978 9.collab: UNAIDSGlobal HIV &amp;amp; AIDS statistics"/>
  <result pre="2019 fact sheet2019 10.collab: World Health OrganizationTB/HIV FACTS 20092009 11.DirlikovERaviglioneMScanoFGlobal" exact="tuberculosis" post="control: toward the 2015 targets and beyondAnn Intern Med20151631525810.7326/M14-221025915859"/>
  <result pre="on the twin epidemics: HIV AND TB Co-infection2014 13.GuptaRKLucasSBFieldingKLLawnSDPrevalence of" exact="tuberculosis" post="in post-mortem studies of HIV-infected adults and children in"/>
  <result pre="with hematologic malignanciesClin Infect Dis201764111532153910.1093/cid/cix16028329354 17.OgimiCEnglundJABradfordMCQinXBoeckhMWaghmareACharacteristics and outcomes of coronavirus" exact="infection" post="in children: the role of viral factors and an"/>
  <result pre="and outcomes of coronavirus infection in children: the role of" exact="viral" post="factors and an Immunocompromised stateJ Pediatric Infect Dis Soc201981212810.1093/jpids/pix09329447395"/>
  <result pre="children: the role of viral factors and an Immunocompromised stateJ" exact="Pediatric" post="Infect Dis Soc201981212810.1093/jpids/pix09329447395 18.DiedrichCRFlynnJLHIV-1/mycobacterium tuberculosis coinfection immunology: how does"/>
  <result pre="factors and an Immunocompromised stateJ Pediatric Infect Dis Soc201981212810.1093/jpids/pix09329447395 18.DiedrichCRFlynnJLHIV-1/mycobacterium" exact="tuberculosis" post="coinfection immunology: how does HIV-1 exacerbate tuberculosis?Infect Immun20117941407141710.1128/IAI.01126-1021245275 19.GeldmacherCZumlaAHoelscherMInteraction"/>
  <result pre="HIV AIDS20127326827522495739 20.AhmedARakshitSVyakarnamAHIV-TB co-infection: mechanisms that drive reactivation of mycobacterium" exact="tuberculosis" post="in HIV infectionOral Dis201622Suppl 1536010.1111/odi.1239027109273 21.EsmailHRiouCBruynEDLaiRPHarleyYXRMeintjesGet al.The immune response"/>
  <result pre="HIV infectionOral Dis201622Suppl 1536010.1111/odi.1239027109273 21.EsmailHRiouCBruynEDLaiRPHarleyYXRMeintjesGet al.The immune response to mycobacterium" exact="tuberculosis" post="in HIV-1-Coinfected personsAnnu Rev Immunol20183660363810.1146/annurev-immunol-042617-05342029490165 22.collab: World Health OrganizationGlobal"/>
  <result pre="personsAnnu Rev Immunol20183660363810.1146/annurev-immunol-042617-05342029490165 22.collab: World Health OrganizationGlobal research on coronavirus" exact="disease" post="(COVID-19)2020 23.Nordic Cochrane Centre The Cochrane Collaboration. Review Manager"/>
  <result pre="DÃ­az A, MartÃ­nez E, Arribas JR, et al. Incidence and" exact="Severity of" post="COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort"/>
  <result pre="28.ChenTLDaiZMoPLiXMaZSongSet al.Clinical characteristics and outcomes of older patients with coronavirus" exact="disease" post="2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective"/>
  <result pre="retrospective studyJ Gerontol A Biol Sci Med Sci20202018 29.LiuWFontanetAZhangPHZhanLXinZTTangFet al.Pulmonary" exact="tuberculosis" post="and SARS, ChinaEmerg Infect Dis200612470770910.3201/eid1204.05026416715587 30.LowJGLeeCCLeoYSSevere acute respiratory syndrome"/>
  <result pre="Sci20202018 29.LiuWFontanetAZhangPHZhanLXinZTTangFet al.Pulmonary tuberculosis and SARS, ChinaEmerg Infect Dis200612470770910.3201/eid1204.05026416715587 30.LowJGLeeCCLeoYSSevere" exact="acute" post="respiratory syndrome and pulmonary tuberculosisClin Infect Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus"/>
  <result pre="29.LiuWFontanetAZhangPHZhanLXinZTTangFet al.Pulmonary tuberculosis and SARS, ChinaEmerg Infect Dis200612470770910.3201/eid1204.05026416715587 30.LowJGLeeCCLeoYSSevere acute" exact="respiratory" post="syndrome and pulmonary tuberculosisClin Infect Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus infection"/>
  <result pre="al.Pulmonary tuberculosis and SARS, ChinaEmerg Infect Dis200612470770910.3201/eid1204.05026416715587 30.LowJGLeeCCLeoYSSevere acute respiratory" exact="syndrome" post="and pulmonary tuberculosisClin Infect Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus infection in"/>
  <result pre="and SARS, ChinaEmerg Infect Dis200612470770910.3201/eid1204.05026416715587 30.LowJGLeeCCLeoYSSevere acute respiratory syndrome and" exact="pulmonary" post="tuberculosisClin Infect Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus infection in an AIDS"/>
  <result pre="acute respiratory syndrome and pulmonary tuberculosisClin Infect Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus" exact="infection" post="in an AIDS patientAIDS200418582983010.1097/00002030-200403260-0002115075525 32.AlfarajSHAl-TawfiqJAAltuwaijriTAMemishZAMiddle East respiratory syndrome coronavirus"/>
  <result pre="Dis20043812e123e12510.1086/42139615227635 31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus infection in an AIDS patientAIDS200418582983010.1097/00002030-200403260-0002115075525 32.AlfarajSHAl-TawfiqJAAltuwaijriTAMemishZAMiddle East" exact="respiratory" post="syndrome coronavirus and pulmonary tuberculosis coinfection: implications for infection"/>
  <result pre="31.WongATYTsangOTYWongKHWongMYFLimWLZhengBJet al.Coronavirus infection in an AIDS patientAIDS200418582983010.1097/00002030-200403260-0002115075525 32.AlfarajSHAl-TawfiqJAAltuwaijriTAMemishZAMiddle East respiratory" exact="syndrome" post="coronavirus and pulmonary tuberculosis coinfection: implications for infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463"/>
  <result pre="in an AIDS patientAIDS200418582983010.1097/00002030-200403260-0002115075525 32.AlfarajSHAl-TawfiqJAAltuwaijriTAMemishZAMiddle East respiratory syndrome coronavirus and" exact="pulmonary" post="tuberculosis coinfection: implications for infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta"/>
  <result pre="an AIDS patientAIDS200418582983010.1097/00002030-200403260-0002115075525 32.AlfarajSHAl-TawfiqJAAltuwaijriTAMemishZAMiddle East respiratory syndrome coronavirus and pulmonary" exact="tuberculosis" post="coinfection: implications for infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A,"/>
  <result pre="East respiratory syndrome coronavirus and pulmonary tuberculosis coinfection: implications for" exact="infection" post="controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A, Das K. Severe Acute"/>
  <result pre="implications for infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A, Das K." exact="Severe" post="Acute Respiratory Syndrome Coronavirus-2 and Pulmonary Tuberculosis Coinfection: Double"/>
  <result pre="for infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A, Das K. Severe" exact="Acute" post="Respiratory Syndrome Coronavirus-2 and Pulmonary Tuberculosis Coinfection: Double Trouble."/>
  <result pre="infection controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A, Das K. Severe Acute" exact="Respiratory" post="Syndrome Coronavirus-2 and Pulmonary Tuberculosis Coinfection: Double Trouble. Res"/>
  <result pre="controlIntervirology2017601â€&quot;2535510.1159/00047790828683463 33.Singh A, Gupta A, Das K. Severe Acute Respiratory" exact="Syndrome" post="Coronavirus-2 and Pulmonary Tuberculosis Coinfection: Double Trouble. Res Square."/>
  <result pre="Gupta A, Das K. Severe Acute Respiratory Syndrome Coronavirus-2 and" exact="Pulmonary" post="Tuberculosis Coinfection: Double Trouble. Res Square. 2020. 10.21203/rs.3.rs-22464/v1. 34.He"/>
  <result pre="A, Das K. Severe Acute Respiratory Syndrome Coronavirus-2 and Pulmonary" exact="Tuberculosis" post="Coinfection: Double Trouble. Res Square. 2020. 10.21203/rs.3.rs-22464/v1. 34.He G,"/>
  <result pre="Dai J, Gamber M, Jiang X, et al. COVID-19 in" exact="tuberculosis" post="patients: a report of three cases. J Med Virol."/>
  <result pre="Scales D, Levine W, Schluger N, O'Donnell M. A Novel" exact="Viral" post="Epidemic Collides with an Ancient Scourge: COVID-19 Associated with"/>
  <result pre="D, Levine W, Schluger N, O'Donnell M. A Novel Viral" exact="Epidemic" post="Collides with an Ancient Scourge: COVID-19 Associated with Tuberculosis."/>
  <result pre="Y, Wang Y, Fleming J, Yu Y. Active or latent" exact="tuberculosis" post="increases susceptibility to COVID-19 and disease severity. MedRxiv BioRxiv"/>
  <result pre="Y, Fleming J, Yu Y. Active or latent tuberculosis increases" exact="susceptibility to" post="COVID-19 and disease severity. MedRxiv BioRxiv 2020; doi: https://doi.org/10.1101/2020.03.10.20033795."/>
  <result pre="Y. Active or latent tuberculosis increases susceptibility to COVID-19 and" exact="disease" post="severity. MedRxiv BioRxiv 2020; doi: https://doi.org/10.1101/2020.03.10.20033795. 39.Tham SM, Lim"/>
  <result pre="Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active" exact="tuberculosis" post="co-infection in an Italian reference hospital. Eur Respir J."/>
  <result pre="2020. 10.1183/13993003.01708-2020. 41.DuRHLiangLRYangCQWangWCaoTZLiMet al.Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: a prospective cohort studyEur Respir J202055200052410.1183/13993003.00524-202032269088"/>
  <result pre="from the Western Cape Province, South Africa2020 43.KarlaSLHawNJLUyJPrevious and active" exact="tuberculosis" post="increases risk of death and prolongs recovery in patients"/>
  <result pre="45.ZhangYDengAHuTChenXZhuangYTanXZhengHSunLLiYZhongHHeJSongTKangMClinical outcome and influencing factors of new cases of coronavirus" exact="pneumonia" post="in Guangdong provinceChin J Epidemiol202041E057 46.Zhang H, Yuan Y."/>
  <result pre="Y. Efficacy and Safety of Nintedanib in the Treatment of" exact="Pulmonary" post="Fibrosis in Patients with Moderate to Severe COVID âˆ’19."/>
  <result pre="the Treatment of Pulmonary Fibrosis in Patients with Moderate to" exact="Severe" post="COVID âˆ’19. https://clinicaltrials.gov/ct2/show/NCT04338802. Accessed 15 May 2020. 47.Motta I,"/>
  <result pre="2020; https://doi.org/10.1016/j.pulmoe.2020.05.002. 48.LiXXuSYuMWangKTaoYZhouYet al.Risk factors for severity and mortality in" exact="adult" post="COVID-19 inpatients in WuhanJ Allergy Clin Immunol2020146111011810.1016/j.jaci.2020.04.00632294485 49.Liu C,"/>
  <result pre="Fleming J, Wang T, Shen S, Wang Y, et al." exact="Severe" post="COVID-19 cases with a history of active or latent"/>
  <result pre="Covid, C.D.C. and Team RSevere Outcomes Among Patients with Coronavirus" exact="Disease" post="2019 (COVID-19) - United States, February 12-march 16, 2020MMWR"/>
  <result pre="living with HIV: a syndemic perspectiveAIDS Behav2020242244224910.1007/s10461-020-02871-932303925 52.collab: Centers for" exact="Disease" post="Control and PreventionHIV Continuum of Care, U.S., 2014, Overall"/>
  <result pre="Route and Sex2017 53.HongKHLeeSWKimTSHuhHJLeeJKimSYet al.Guidelines for laboratory diagnosis of coronavirus" exact="disease" post="2019 (COVID-19) in KoreaAnn Lab Med202040535136010.3343/alm.2020.40.5.35132237288 54.PiatekASVanCMAlexanderHCogginWLRehrMVanKSet al.GeneXpert for"/>
  <result pre="et al. Bronchoalveolar lavage enzyme-linked immunospot for diagnosis of smear-negative" exact="tuberculosis" post="in HIV-infected patients. PLoS One. 2012;7(6). 57.collab: World Health"/>
  <result pre="in HIV-infected patients. PLoS One. 2012;7(6). 57.collab: World Health OrganizationLatent" exact="tuberculosis" post="infection Updated and consolidated guidelines for programmatic management2018 58.SavarinoAExpanding"/>
  <result pre="HIV-infected patients. PLoS One. 2012;7(6). 57.collab: World Health OrganizationLatent tuberculosis" exact="infection" post="Updated and consolidated guidelines for programmatic management2018 58.SavarinoAExpanding the"/>
  <result pre="A reviewJ Drug Metab Toxicol201672072 64.collab: National Institute of HealthCoronavirus" exact="Disease" post="2019 (COVID-19) Treatment Guidelines. From NIH website2020 65.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine"/>
  <result pre="website2020 65.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J200526910.1186/1743-422X-2-6916115318 66.ColsonPRolainJMRaoultDChloroquine for the 2019 novel coronavirusInt"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; https://doi.org/10.1093/cid/ciaa237."/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; https://doi.org/10.1093/cid/ciaa237. 68.Tobaiqy"/>
  <result pre="74.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost20201851094109910.1111/jth.1481732220112 75.AlhazzaniWMÃ¸ller MortenHArabiYMLoebMGongMNFanEet al.Surviving"/>
  <result pre="guidelines on the management of critically ill adults with coronavirus" exact="disease" post="2019 (COVID-19)Intensive Care Med20204885488710.1007/s00134-020-06022-5"/>
 </snippets>
</snippetsTree>
